P825: FACTOR D INHIBITION WITH ORAL BCX9930 MONOTHERAPY LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA NAÏVE TO C5 INHIBITORS

Detalles Bibliográficos
Autores principales: McDonald, A., Malherbe, J. L. R., Kulasekararaj, A., Füreder, W., Griffin, M., Cornpropst, M., Farmer, M. K., Kargl, D., Collins, D., Sheridan, W., Risitano, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430448/
http://dx.doi.org/10.1097/01.HS9.0000846184.35066.7a

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430448/
http://dx.doi.org/10.1097/01.HS9.0000846184.35066.7a

Ejemplares similares